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Lanthanide-based peptide biosensor to monitor CDK4/cyclin D 
kinase activity †  
Juan A. González-Vera,a David Bouzada, b Céline Bouclier,a Eugenio Vázquez,b and May C. Morris*a 
We describe a lanthanide biosensor that responds to CDK4 kinase 
activity in melanoma cell extracts through a significant and dose 
dependent increase in luminescence, thanks to sensitization of a 
DOTA[Tb3+] complex incorporated into a CDK4 substrate peptide by 
a unique tryptophan residue in an adjacent phosphoaminoacid 
binding moiety. 
Phosphorylation triggered by extracellular signals and carried 
out by protein kinases is a fundamental signal transduction 
mechanism involved in the regulation of most basic processes 
in eukaryotic cells.1 Consequently, chemical tools that perturb 
the function of protein kinases and fluorescent probes that 
enable imaging of their spatio-temporal dynamics offer means 
of dissecting their behaviour and unravelling the complexity of 
signalling cascades in which they are involved. Fluorescent 
reporters of protein kinases constitute potent tools for probing 
changes in the subcellular localization and activation of these 
enzymes, thereby allowing to re-examine and address 
questions relative to their biochemical function and regulation 
in complex biological samples and in living cells in a sensitive 
and non-invasive fashion.2 Accordingly, a number of fluorescent 
peptide biosensors for monitoring kinase activity, based on 
environment-sensitive3-6 or chelation-enhanced7-9 
fluorophores, have been described. More recently, lanthanides 
have also been applied to the design of kinase biosensors, often 
taking advantage of the chelating effect of the phosphate anion 
to induce the formation of luminescent lanthanide 
complexes.10-16 Indeed lanthanide-based probes are particularly 
attractive as their luminescence is significantly longer than the 
nanosecond lifetimes of organic fluorophores. Moreover their 
use in biological applications allows to circumvent issues 
associated with organic dyes relative to background 
fluorescence of living cells.17 
CDK4/cyclin D is a heterodimeric member of the cyclin-
dependent kinase family involved in regulation of cell cycle 
progression at the G1/S transition through phosphorylation of 
the Retinoblastoma tumor suppressor protein (Rb).18  This 
kinase is frequently hyperactivated in several human cancers, 
and in particular in melanoma, due to overexpression or 
mutation of CDK4, genetic amplification of cyclin D, methylation 
or loss of function of p16INK4a.19-22 Recently, our group 
developed an environmentally-sensitive fluorescent peptide 
biosensor to probe CDK4/Cyclin D activity, which was further 
implemented to quantify kinase activity in skin biopsies and 
melanoma xenografts.23 Herein we describe a luminescent, 
terbium-based peptide biosensor that reports on CDK4 activity 
in melanoma cell extracts with much greater sensitivity than the 
previously reported TAMRA-labelled biosensor. Tb-CDKACT4-
OH biosensor is a bipartite peptide derived from the backbone 
of the first CDKACT4 biosensor, comprising a CDK4-specific 
substrate sequence derived from Rb and a phosphoamino acid 
binding domain (PAABD) derived from the interface of the WW 
domain of Pin1 with a phosphopeptide.23 To generate the Tb-
based biosensor, we took advantage of the unique Trp residue 
in the PAABD and further incorporated a terbium complex in the 
substrate moiety, proximal to the CDK4-specific 
phosphorylation site,  thereby generating a luminescent 
transduction unit which would emit luminescence when 
brought into spatial proximity with the Trp antenna, following 
phosphorylation of the substrate moiety and its consequent 
recognition by the PAABD (Figure 1A). 
Peptide biosensor variants harbouring either the native 
CDK4-specific substrate sequence, or the corresponding 
synthetic phosphopeptide were prepared by Fmoc-based solid-
phase peptide synthesis. The Tb3+ complex was introduced into 
the peptide sequence as DOTA-Tb3+ maleimide (chelating 
macrocycle DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid) through a Cys residue. Peptide identities and 
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purities were confirmed by electrospray mass spectrometry and 
high-performance liquid chromatography (HPLC) analysis. 























Fig. 1 A) Schematic representation of the biosensor. Upon phosphorylation, the 
phosphopeptide should bind to the recognition domain (PAABD), leading to a 
conformational change that should bring together the sensitizing antenna and the 
terbium complex, resulting in an increase in the luminescence emission. B) The 
peptide sequence of the designed biosensors, where the phosphorylatable 
residue is bold and φ = Cys(DOTA-Tb3+). 
 
To determine the optimal position of the lanthanide 
complex within the susbtrate sequence relative to the Trp 
antenna in the PAABD moiety, a small peptide library was 
prepared, in which the chelating DOTA unit was positioned at 
various sites (-2, -4, and -6 positions) relative to the 
phosphorylatable serine residue (Figure 1B). In order to validate 
the functionality of these biosensor peptides and to assess their 
dynamic range of response, we first determined the increase in 
luminescence intensity between the phosphorylated and the 
corresponding unphosphorylated variants. We found that the 
greatest response was observed when the lanthanide complex 
was incorporated at position -2 (peptides Tb-CDKACT-OH and 
Tb-CDKACT-P; Figure S1). Indeed, upon excitation at 280 nm, 
the synthetic phosphate-containing biosensor Tb-CDKACT-P, 
showed a significant increase (3.2-fold) in the typical 
luminescence emission bands of the terbium ion, at 488, 544, 
585, and 620 nm (Figure 2A). However, when the unique Trp 
residue in the PAABD moiety was replaced by Ala [peptides Tb-
CDKACT-OH(-W) and Tb-CDKACT-P(-W)], no increase in 
luminescence was observed, demonstrating that the 
tryptophan antenna is indeed required for sensitization (Figure 
2B). Furthermore, when an independent PAABD peptide was 
incubated with the DOTA-Tb3+ labelled Rb phosphopeptide (Tb-
Rb-P), no terbium luminescence was observed, indicating that 
an intramolecular link was required for proper spatial 
positioning between the tryptophan residue and the terbium 
complex (Figure S2). Moreover, we found that the luminescent 
response of Tb-CDKACT4-P relative to Tb-CDKACT4-OH 
increased with the temperature of the reaction (between 25 ºC 
and 37 ºC), indicating that the response involving recognition of 
the phospho-substrate by the PAABD is a dynamic process that 





























Fig. 2 A) Time-resolved luminescence emission (lex = 280 nm, 0.4 ms delay time) 
of a 5 µM solution of the phosphopeptide Tb-CDKACT4-P (solid line) and the 
corresponding unphosphorylated biosensor Tb-CDKACT4-OH (dashed line) at 30 
ºC, in 50 mM HEPES buffer, pH 7.5, 100 mM NaCl. B) Time-resolved luminescence 
emission (lex = 280 nm, 0.4 ms delay time) of a 5 µM solution of the 
phosphopeptide Tb-CDKACT4-P(-W) (solid line) and the corresponding 
unphosphorylated biosensor Tb-CDKACT4-OH(-W) (dashed line) at 30 ºC, in 50 
mM HEPES buffer, pH 7.5, 100 mM NaCl. 
 
When further assessing the best working conditions for 
biosensor application, we observed that overall luminescent 
signal of Tb-CDKACT-OH and Tb-CDKACT-P increased with the 
concentration of the peptide. However, the dynamic range of 
the reporter (ratio between Tb-CDKACT4-P and Tb-CDKACT4-
OH) remained within the same average value of 3.2-3.7-fold, 
indicating that the sensitivity of response was independent of 
biosensor concentration (Figure 3A). Furthermore, when the 
same peptides (Tb-CDKACT-OH and CDKACT-P) were labelled 
with a variety of thiol reactive derivative fluorophores (4-DMN, 
TP-2Rho, Bodipy, coumarine, oxazine, Cy3, Cy5, TAMRA, FITC 
and merocyanine 53), none of them responded to the same 
extent as the peptides labelled with the terbium complex, 
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emphasizing the much greater sensitivity of the lanthanide 







Fig. 3 A) Luminescence difference at 545 nm between Tb-CDKACT4-P and Tb-
CDKACT4-OH, at increasing concentrations (5, 10, 25 and 50 µM) of a solution of 
the corresponding peptide in 50 mM HEPES buffer, pH 7.5, 100 mM NaCl (lex = 
280 nm). B) Comparison of the luminescence difference between CDKACT4-P and 
CDKACT4-OH, labelled with either diverse fluorophores or the DOTA-Tb3+ 
complex. 
 
We therefore further implemented the Tb-CDKACT4-OH 
peptide biosensor to probe CDK4/Cyclin D kinase activity in 
A375 melanoma cell extracts. Incubation of 25 µM biosensor 
with 40 µg of cell extracts resulted in a robust 3-fold increase in 
luminescence (Figure 4A), corresponding to the maximal 
increase in luminescence observed between Tb-CDKACT4-OH 
and its synthetic phospho-counterpart (Figure 3A), highlighting 
the robustness of the biosensor in a complex environment, i.e. 
cell extracts. Moreover, Tb-CDKACT4-OH responded to A375 
melanoma cell extracts in a dose-dependent fashion, between 
5 and 100 µg, thereby indicating its utility and potential for 
quantification of kinase activities within this range (Figure 4B). 
In contrast, addition of BSA (40-200 µg), did not have any 
significant impact on the luminescence of the biosensor, 
indicating that Tb-CDKACT4 does not simply respond to the 
presence of unrelated proteins (Figure 4B). The specificity of 
response to CDK4 activity was further confirmed by incubation 
with melanoma cell extracts (40 µg) pretreated with different 
concentrations of the CDK4-specific inhibitor Abemaciclib 
(LY2835219), or the pan-CDK inhibitor Roscovitine, which 
inhibits several CDKs (CDK2, CDK1, CDK5, CDK7, CDK9), but not 
CDK4/CDK6. Whilst the luminescent signal emitted by the 
biosensor upon incubation with A375 cell extracts remained 
unperturbed when incubated with extracts from Roscovitine-
treated cells, it was reduced in a dose-dependent fashion upon 
incubation with extracts from Abemaciclib-treated cells (Figure 
4C). Moreover, the concentration-dependent luminescent 
response reported by Tb-CDKACT biosensor mirrored the 
inhibition profile of A375 cell proliferation (Figure 4D), revealing 
that 50% inhibition of both cell proliferation and CDK4 activity 
were achieved at a concentration of 1uM Abemaciclib in this cell 
line. In contrast, neither Abemaciclib, nor Roscovitine had any 
significant effect on the luminescence of Tb-CDKACT4-OH 










































Fig. 4 A) Time-resolved luminescence emission (0.4 ms delay time) of a 25 µM 
solution of the Tb-CDKACT4-OH biosensor at 30 ºC, in 50 mM HEPES buffer, pH 
7.5, 100 mM NaCl (dashed line), and the same peptide in the presence of 40 µg of 
A375 melanoma cell extracts (solid line). B) Tb-CDKACT4-OH peptide biosensor 
responds to A375 melanoma cell extracts in a dose-dependent fashion, but not 
upon addition of BSA. C) Tb-CDKACT4-OH biosensor responds to inhibition of 
CDK4/Cyclin D activity in A375 melanoma cell extracts by Abemaciclib and 







































COMMUNICATION Journal Name 
4  |  J. Name. , 2012, 00,  1-3  This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
 In summary, we have engineered the first lanthanide-based 
peptide biosensor of CDK4 and have demonstrated that its 
luminescence intensity is significantly and specifically enhanced 
upon phosphorylation by this kinase in melanoma cell extracts. 
Our biosensor displays remarkable sensitivity owing to its 
original design, which involves the intramolecular sensitization 
of a luminescent DOTA[Tb3+] macrocyclic complex by a 
sensitizing tryptophan antenna within the PAABD upon 
phosphorylation of the substrate moiety by CDK4. The 
luminescent properties of this biosensor make it a performant 
tool for probing kinase activities in cell extracts, thereby 
providing major improvement over assays which report on the 
kinase activity of purified recombinant enzymes, since cell 
extracts constitute a complex yet more physiological 
environment. We have further demonstrated that this 
biosensor mirrors the response of living cells to inhibition by 
kinase-specific inhibitor, thereby highlighting the attractivity of 
this technology for drug discovery purposes. 
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